Trial Profile
A Multicenter, Open Label, Single-arm Pilot Study to Evaluate the Efficacy and Safety of Oral Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Palmoplantar pustulosis
- Focus Therapeutic Use
- Acronyms APLANTUS
- 01 Oct 2021 Results reporting clinical findings of apremilast for treatment of PPP over 20 weeks published in the Journal of the European Academy of Dermatology and Venereology
- 24 Sep 2021 Results published in the ClinicalTrials.gov Trial Registry
- 21 Aug 2019 Status changed from recruiting to completed.